Phathom Pharmaceuticals to announce Q2 2026 financial results

1 min read Updated on 20 Jul 2026, 06:52 PM

Reviewed by

Riya DScanX News Team

AI Summary

Phathom Pharmaceuticals, Inc. is set to announce its second quarter 2026 financial results on July 30, 2026, via a live webcast at 8:00 am EDT. The company will provide a business update alongside the financial disclosure. A recording of the event will be available for 90 days.

*this image is generated using AI for illustrative purposes only.

Phathom Pharmaceuticals, Inc. will report its second quarter 2026 financial results and provide a business update on Thursday, July 30, 2026. The announcement is significant for investors tracking the progress of the biopharmaceutical company's commercialization efforts for its gastrointestinal treatments. A live webcast is scheduled for 8:00 am EDT to discuss the quarterly performance and strategic updates.

The webcast can be accessed through the Events & Presentations section of the Phathom website. Investors and interested parties can listen to the management discuss the financial outcomes and operational milestones. For those unable to attend the live session, a recording will be made available and accessible for 90 days after the conclusion of the call.

Phathom Pharmaceuticals focuses on the development and commercialization of novel treatments for gastrointestinal diseases. The company holds exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada. Its current product portfolio includes VOQUEZNA tablets for heartburn associated with Non-Erosive GERD and Erosive GERD, as well as combination therapies for H. pylori infection.

Key Event Details

Detail	Information
Event	Q2 2026 Financial Results & Business Update
Date	Thursday, July 30, 2026
Time	8:00 am EDT
Access	Phathom Investors Website
Recording Availability	90 days post-event

What market share targets is Phathom aiming for in the U.S. and European GERD markets by the end of 2026?

How will the company's commercialization strategy evolve following the Q2 earnings update?

What additional indications for vonoprazan might be explored beyond the current portfolio?

Analyst Rating

The rating update comes from analyst Matthew Caufield of HC Wainwright & Co. The firm has chosen to sustain its existing position on the stock without adjusting the valuation target.